Heterogeneity in influenza seasonality and vaccine effectiveness in Australia, Chile, New Zealand and South Africa: early estimates of the 2019 influenza season

Sheena G Sullivan[1], Carmen S Arriola[2], Judy Bocacao[3], Pamela Burgos[4], Patricia Bustos[5], Kylie S Carville[6], Allen C Cheng[7,8], Monique BM Chilver[9], Cheryl Cohen[10], Yi-Mo Deng[11], Nathalie El Omeiri[12], Rodrigo A Fasce[13], Orienka Hellferscee[10], Q Sue Huang[3], Cecilia Gonzalez[4], Lauren Jelley[3], Vivian KY Leung[1], Liza Lopez[14], Johanna M McAnerney[10], Andrea McNeill[14], Maria F Olivares[15], Heidi Peck[11], Viviana Sotomayor[15], Stefano Tempia[2,10,16,17], Natalia Vergara[15], Anne von Gottberg[10], Sibongile Walaza[10], Timothy Wood[14]

1. World Health Organization (WHO) Collaborating Centre for Reference and Research on Influenza, Royal Melbourne Hospital, and Doherty Department, University of Melbourne, at the Peter Doherty Institute for Infection and Immunity, Melbourne, Australia
2. Influenza Division, Centers for Disease Control and Prevention, Atlanta, United States
3. National Influenza Centre, Institute of Environmental Science and Research, Wellington, New Zealand
4. Programa Nacional de Inmunizaciones, Ministerio de Salud, Santiago, Chile
5. Sección de Virus Respiratorios y Exantematicos, Instituto de Salud Publica de Chile, Santiago, Chile
6. Victorian Infectious Diseases Reference Laboratory, Royal Melbourne Hospital, at the Peter Doherty Institute for Infection and Immunity, Melbourne, Australia
7. School of Public Health and Preventive Medicine, Monash University, Melbourne, Australia
8. Department of Infectious Diseases, Alfred Health, and Central Clinical School, Monash University, Melbourne, Australia
9. Discipline of General Practice, University of Adelaide, Adelaide, Australia
10. National Institute for Communicable Diseases, Johannesburg, South Africa
11. WHO Collaborating Centre for Reference and Research on Influenza, Royal Melbourne Hospital, at the Peter Doherty Institute for Reference and Research on Influenza, Melbourne, Australia
12. Pan American Health Organization(PAHO)/WHO Regional Office for the Americas, Washington, United States
13. Subdepartamento de Enfermedades Virales, Instituto de Salud Publica de Chile, Santiago, Chile
14. Health Intelligence Team, Institute of Environmental Science and Research, Wellington, New Zealand
15. Departamento de Epidemiologia, Ministerio de Salud, Santiago, Chile
16. Influenza Program, Centers for Disease Control and Prevention, Pretoria, South Africa
17. MassGenics, Duluth, United States

Correspondence: Sheena G Sullivan (Sheena.Sullivan@influenzacentre.org)

We compared 2019 influenza seasonality and vaccine effectiveness (VE) in four southern hemisphere countries: Australia, Chile, New Zealand and South Africa. Influenza seasons differed in timing, duration, intensity and predominant circulating viruses. VE estimates were also heterogeneous, with all-ages point estimates ranging from 7–70% (I^2: 33%) for A(H1N1) pdm09, 4–57% (I^2: 49%) for A(H3N2) and 29–66% (I^2: 0%) for B. Caution should be applied when attempting to use southern hemisphere data to predict the northern hemisphere influenza season.

In Australia, Chile, New Zealand and South Africa, sentinel surveillance is conducted in primary care and/or hospitals to monitor the timing, intensity and impact of influenza seasons, and to estimate influenza vaccine effectiveness (VE). While the influenza epidemics of these four southern hemisphere countries often coincide, the type of epidemic experienced can vary. Nevertheless, the influenza season experienced in southern hemisphere countries has sometimes been interpreted as a forewarning to the northern hemisphere [1]. Here, we describe the heterogeneity experienced during the 2019 influenza season in these four countries and provide early VE estimates.

Influenza surveillance systems

The sentinel surveillance systems used in this analysis are described in detail in the Table. For Australia, influenza-like illness (ILI) surveillance data came from the Australian Sentinel Practices Research Network (ASPREN), supplemented by the Victorian Sentinel Practice Influenza Network (VicSPIN) [2]. Hospital surveillance data were obtained from the Influenza Complications Alert Network (FluCAN) [3]. In Chile, severe acute respiratory infection (SARI) sentinel surveillance included seven sentinel hospitals distributed across six of 16 administrative regions [4]. In New Zealand, ILI surveillance leverages general practice-registered patients in all 20 district health boards,

Table

Summary of key differences in case and exposure ascertainment for syndromic and virological surveillance and vaccine effectiveness estimation, four southern hemisphere countries, 2019 influenza season

Characteristic	Australia	Chile	New Zealand	South Africa
Source populations[a]	ILI: 394 GPs at sentinel general practices nationwide participate in syndromic ILI surveillance; 222 GPs participate in swab testing; 21 sentinel hospitals nation-wide	Seven sentinel hospitals in 6/16 regions	86 sentinel practices (ILI patients) in 20 district health boards and four hospitals (SARI patients)	Syndromic: a healthcare provider network Virological and VE: Sentinel general practices (ILI patients) in 6/9 regions
Period used for weekly rates	ILI: weeks 1–52 2019: weeks 1–39 Hospitals: weeks 14–44 2019: weeks 14–39	Weeks 1–52 2019: weeks 10–33	Weeks 18–39 2019: weeks 18–39	Weeks 1–52 2019: weeks 1–38
Clinical case definition	ILI: fever or history of fever AND cough, fatigue/malaise Hospitals: suspected influenza (not SARI)	SARI: history of fever, or measured fever of ≥ 38 C° AND cough AND onset within the last 10 days AND hospitalisation	ILI: acute respiratory illness with a history of fever or measured fever of ≥ 38 °C, AND cough, AND onset within the past 10 days SARI: as above, but requiring hospitalisation	ILI: measured fever (≥ 38 °C) or history of fever, cough, onset ≤ 10 days
Virological testing	ILI: Around 50% of patients are swabbed for testing by RT-PCR at SA Pathology, Adelaide or the NIC, Melbourne. Hospitals: RT-PCR testing done at each hospital. Sequencing performed by WHOCCRRI, Melbourne.	RT-PCR or direct immunofluorescence followed by RT-PCR-positive for pan-negative and influenza-positive specimens for subtyping. Testing and sequencing performed at NIC, Santiago.	RT-PCR testing at NIC, Wellington. Sequencing performed by WHOCCRRI, Melbourne.	RT-PCR testing by NIC, Johannesburg. Sequencing performed by WHOCCRRI, Melbourne or Worldwide Influenza Centre, Crick Institute, London.
Study period for VE estimation	ILI: 28 Apr 2019–9 Oct 2019 Hospitals: 1 Apr 2019–16 Aug 2019	SARI: 4 Mar 2019–18 Aug 2019	ILI and SARI: 29 Apr 2019–29 Sep 2019	ILI: 15 Apr 2019–18 Aug 2019
Cases/controls for VE estimates	ILI: test-positive cases vs test-negative controls Hospitals: test-positive cases; control are the next admitted test-negative patient (≤ 2 weeks)	Test-positive cases vs test-negative controls	Test-positive cases vs test-negative controls	Test-positive cases vs test-negative controls
Vaccination status ascertainment	Medical record, self-report or vaccination registry	Medical record or vaccination registries (no verbal reports)	Vaccination registry and self-report	Medical record or self-reported
Vaccination coverage among influenza-negative controls included in VE estimates[b]	Overall: 49% ILI; 47% hospitals Adults: 46% ILI; 41% hospitals Children: 26% ILI; 33% hospitals Elderly: 78% ILI; 73% hospitals	Overall: 61% SARI[c] Adults: 41% SARI[c] Children: 72% SARI[c] Elderly: 64% SARI[c]	Overall: 26% ILI; 33% SARI Adults: 26% ILI; 36% SARI Children: 9% ILI Elderly: 70% ILI; 66% SARI	Overall: 11% ILI Adult: 11% ILI Children: 9% ILI Elderly: 35% ILI
Vaccines licensed	< 5 years: Flu Quadri Junior (Sanofi) < 65 years: Afluria Quad (Seqirus), FluQuadri (Sanofi) and Fluarix Tetra (GSK) ≥ 65 years: Fluad (Seqiris; trivalent with B/Yamagata component)	Influvac (Abbott) (inactivated subunit vaccine) TIV included a B/Victoria-lineage component	6–35 months: Fluarix Tetra (GSK) ≥ 3 years: FluQuadri (Sanofi), Influvac (Abbott) ≥ 5 years only: Afluria Quad (Seqiris)	Vaxigrip (Sanofi Pasteur) (inactivated split-virion vaccine) and Influvac (Abbott) (inactivated subunit vaccine) All TIV
Target groups for vaccination	Recommended for all. Free for pregnant women; people aged < 5 years or ≥ 65 years; Aboriginal and Torres Strait Islander peoples; people aged 5–64 years with chronic conditions.	Pregnant women from 13 weeks gestation; children aged 6–59 months, adults aged ≥ 65 years; poultry and pig farm workers; patients with chronic conditions aged 5–64 years; carriers of some risk conditions; healthcare workers.	Pregnant women; people aged ≥ 65 years; people aged < 65 years with a medical condition that increases their risk of developing complications from influenza and the condition is specified in the Influenza Immunisation Programme eligibility criteria; children aged ≤ 4 years with previous hospitalisation for respiratory illness or with a history of significant respiratory illness.	Pregnant women at all stages of pregnancy, including the post-partum period; HIV-infected individuals; adults or children who are at high risk for influenza complications because of underlying medical conditions or who are receiving regular medical care for conditions such as chronic pulmonary disease; persons aged ≥ 65 years.

GP: general practice; GSK: Glaxo Smith Kline; ILI: influenza-like illness; NIC: National Influenza Centre; QIV: quadrivalent inactivated vaccine; SARI: severe acute respiratory illness; TIV: trivalent inactivated vaccine; VE: vaccine effectiveness; WHOCCRRI: World Health Organization Collaborating Centre for Reference and Research on Influenza.

[a] Numbers are provided for 2019.

[b] Children: 6 months–17 years of age; Adults: 18–64 years of age; Elderly: ≥ 65 years of age.

[c] Only patients in a target group for vaccination are included in SARI surveillance in Chile so these numbers do not necessarily reflect coverage in the whole population.

Check for updates

ca 540,000, while SARI surveillance includes four public hospitals in Auckland and Counties Manukau District Health Boards [5]. Syndromic surveillance data from South Africa came from outpatient presentations to a large private healthcare provider network, based on International Classification of Diseases (ICD-10) codes for pneumonia and influenza (J9-J11) [6,7]. Virological surveillance in South Africa was conducted through the Viral Watch network [8].

Seasonality

Weekly 2019 influenza activity rates, e.g. ILI consultations per week, were plotted against the mean weekly rate for influenza seasons from 2013 to 2018. All rates were smoothed using a 3-week moving average. The moving epidemic method (MEM) package [9] in R software version 3.6.1 (R Foundation, Vienna, Austria) was used for calculating means and seasonal thresholds using default values to show the onset and intensity of the season (Figure 1A). The specifications used for the MEM may differ from published national surveillance reports. The onset and peak of the influenza season was at least 5 weeks early in Australia and 1 to 2 weeks early in Chile, New Zealand and South Africa. Activity was well above expected levels in South Africa and very high in Chile, but only reached moderate levels in Australia or New Zealand. The seasons experienced in Chile and South Africa were also much shorter in duration than in Australia and New Zealand.

Virological data

Virological data are shown in Figure 1B and highlight the variation in predominant viruses circulating among countries. For example, while influenza A(H3N2) virus clearly predominated in South Africa and was detected at very high levels with the positivity reaching 80% during the peak period, the predominant virus in Chile was A(H1N1)pdm09. In New Zealand, both influenza A and B viruses were detected; however, their relative frequency differed between ILI and SARI surveillance, with B viruses detected among roughly half (51%; 604/1,179) of ILI patients but only a quarter (27%; 104/385) of SARI patients.

Genetic characterisation of selected viruses showed further differences among countries, although the number of samples characterised was small. Circulating A(H1N1)pdm09 viruses were similar, with most falling into subclade 6B.1A-P5 in Australia, New Zealand and Chile. Differences in the predominant circulating clade were observed for A(H3N2). Of 192 viruses sequenced in Australia, 186 were 3C.2a1b (3C.2a1b+131K: n = 182; 3C.2a1b+135K: n = 4), with just six 3C.3a. The majority of A(H3N2) viruses sequenced in New Zealand also clustered in clade 3C.2a1b. In Chile, of 31 viruses sequenced, 13 fell into the clade 3C.2a1b and 18 to 3C.3a. A limited selection of only 10 viruses from South Africa suggested co-circulation of 3C.2a1b+131K, 3C.2a1b+135K and 3C.3a viruses. For influenza B, nearly all viruses characterised in Australian primary care surveillance (107/108) and in New Zealand

(167/169) were B/Victoria lineage viruses, while all 11 influenza B viruses characterised in Chile were B/Yamagata.

Vaccine effectiveness estimation

The virological data depicted in Figure 1B formed the basis for VE estimation. All systems followed a test-negative design, where the odds ratio (OR) comparing the odds of vaccination among test-positive cases vs test-negative controls was used to derive VE, i.e. $VE = (1 − OR_{adj}) \times 100\%$ [10]. Estimates were made separately for each country, virus and age group, incorporating covariates considered important by each site (Figure 2). The heterogeneity among estimates within each virus/age group combination was measured by I^2 and τ^2 [11]. All networks were able to provide data for the A(H3N2) VE. Too few A(H1N1)pdm09 and B cases were detected in South Africa to enable VE estimation.

For A(H1N1)pdm09, heterogeneity was low overall (I^2: 22%). For adults, although heterogeneity was not high (I^2: 58%), VE estimates ranged from −6% (95% compatibility interval (CI): −96 to 42) in New Zealand to 72% (95% CI: 51–84) among people in a target group for vaccination in Chile. Only Chile was able to provide VE estimates for children (65%; 95% CI: 49–76) and elderly, i.e. adults aged ≥ 65 years (74%; 95% CI: 51–86).

For A(H3N2), heterogeneity was moderate overall (I^2: 49%), but higher for adults (I^2: 59%). In Australia, South Africa and New Zealand hospitals, VE point estimates ranged from 34% to 57% across age groups; however, in Chile and New Zealand primary care, estimates were often close to or beyond the null.

For influenza B, heterogeneity was low overall (I^2: 0%), despite differences in the predominant lineage and the use of trivalent vaccine in Chile but quadrivalent in New Zealand and Australia. Overall VE was lowest in Chile (29%; 95% CI: −23 to 59). Here, the B component for trivalent vaccines included a B/Victoria-like virus, but most viruses circulating were B/Yamagata thereby suggesting this low VE may be attributable to lineage mismatch. Only one VE estimate was available for elderly adults (Chile: 44%; 95% CI: −10 to 72) and children (Australia: 55%; 95% CI: 20–76).

Discussion

We have shown that within countries of the southern hemisphere, the timing, duration and intensity of the influenza seasons, the predominant circulating viruses, and VE all varied in the 2019 influenza season, even between neighbouring countries such as Australia and New Zealand. Similar observations have been reported from Europe [9]. Thus, it appears that activity in one country is not indicative of activity in another country, even when influenza seasons are contemporaneous.
The early VE estimates for the 2019 influenza season in the southern hemisphere presented here were highest for influenza A(H1N1)pdm09 and lowest for

FIGURE 1

Influenza activity (A) and influenza detections (B) for Australia, Chile, New Zealand and South Africa, 2019 influenza season

A. Influenza activity plots

B. Influenza detections by type and subtype

ILI: influenza-like illness; P&I: pneumonia and influenza; SARI: severe acute respiratory infection.

Influenza activity plots (A) show the intensity of the 2019 influenza season compared with the average for 2013 to 2018. The point at which 2019 activity crossed baseline thresholds set by the prior 6 years' data are marked with crosses. No post-season thresholds were estimated for New Zealand.

Influenza detections by type and subtype (B) for patients enrolled in hospital and primary care surveillance for VE estimation. The data used in vaccine effectiveness estimation are a subset restricted to those patients with complete information and recruited within the weeks used for estimation (Table).

Figure 2

Early vaccine effectiveness estimates against influenza A(H1N1)pdm09, A(H3N2) and B by age group and setting, Australia, Chile, New Zealand and South Africa, 2019 influenza season

Influenza A(H1N1)pdm09

Network	Setting	Positive V	Positive UV	Negative V	Negative UV	VE% (95% CI)
All patients						
Australia	Primary care	27	70	1,065	1,055	62 (39 to 78)
New Zealand	Primary care	20	68	225	592	7 (−60 to 47)
Australia	Hospital	43	120	685	776	70 (49 to 82)
New Zealand	Hospital	9	25	185	373	54 (−8 to 80)
Chile	Hospital	108	244	756	475	70 (60 to 77)
						$I^2 = 33.3$ $\tau^2 = 0.0048$
Adults (18−64 years)						
Australia	Primary care	16	47	647	721	62 (34 to 80)
New Zealand	Primary care	16	40	138	367	−6 (−96 to 42)
Chile	Hospital	23	112	107	153	72 (51 to 84)
						$I^2 = 58.4$ $\tau^2 = 0.026$
Elderly (≥ 65 years)						
Chile	Hospital	60	99	397	226	65 (49 to 76)
Children (< 18 years)						
Chile	Hospital	25	33	252	96	74 (51 to 86)

Vaccine effectiveness (−20, 0, 50, 100)

Influenza A(H3N2)

| Network	Setting	Positive V	Positive UV	Negative V	Negative UV	VE% (95% CI)
All patients						
Australia	Primary care	274	434	1,065	1,055	37 (24 to 49)
New Zealand	Primary care	108	309	225	592	4 (−29 to 29)
South Africa	Primary care	39	665	38	320	53 (23 to 72)
Australia	Hospital	325	303	685	776	43 (22 to 59)
New Zealand	Hospital	24	52	185	373	57 (21 to 76)
Chile	Hospital	32	16	649	322	6 (−75 to 49)
						$I^2 = 49.3$ $\tau^2 = 0.013$
Adults (18−64 years)						
Australia	Primary care	139	246	647	721	39 (23 to 53)
New Zealand	Primary care	63	168	138	367	0 (−41 to 30)
South Africa	Primary care	24	374	22	199	47 (−1 to 72)
						$I^2 = 54.8$ $\tau^2 = 0.025$
Elderly (≥ 65 years)						
Australia	Primary care	93	36	308	76	50 (16 to 70)
New Zealand	Primary care	36	11	64	25	−28 (−190 to 44)
New Zealand	Hospital	22	17	87	41	39 (−27 to 71)
Chile	Hospital	24	10	397	226	−24 (−167 to 43)
						$I^2 = 7.43$ $\tau^2 = 0.007$
Children (< 18 years)						
Australia	Primary care	38	148	96	242	34 (−2 to 58)
New Zealand	Primary care	9	130	23	200	40 (−34 to 73)
Chile	Hospital	8	6	252	96	54 (−40 to 85)
						$I^2 = 0$ $\tau^2 = 0$

Vaccine effectiveness (−20, 0, 50, 100)

Influenza B

Network	Setting	Positive V	Positive UV	Negative V	Negative UV	VE% (95% CI)
All patients						
Australia	Primary care	44	188	1,065	1,055	63 (46 to 74)
New Zealand	Primary care	8	45	225	592	56 (38 to 69)
Australia	Hospital	140	367	685	776	52 (34 to 65)
New Zealand	Hospital	6	42	185	373	66 (23 to 85)
Chile	Hospital	32	28	756	475	29 (−23 to 59)
						$I^2 = 0$ $\tau^2 = 0$
Adults (18−64 years)						
Australia	Primary care	22	79	647	721	73 (57 to 84)
New Zealand	Primary care	5	13	138	367	−2 (−192 to 64)
New Zealand	Hospital	4	17	60	101	60 (−23 to 87)
						$I^2 = 0$ $\tau^2 = 0$
Elderly (≥ 65 years)						
Chile	Hospital	21	18	397	226	44 (−10 to 72)
Children (< 18 years)						
Australia	Primary care	19	104	96	242	58 (29 to 77)

Vaccine effectiveness (−20, 0, 50, 100)

CI: compatibility interval; V: vaccinated; UV: unvaccinated; VE: vaccine effectiveness.

I^2 and τ^2 are shown for measures of heterogeneity.

Estimates for Chile only include patients in a target group for vaccination; Australia used adjuvanted TIV for individuals ≥ 65 years of age.

Covariate adjustment: Australia primary care estimates adjusted for week (restricted cubic spline) and age group (where appropriate); Australia hospital estimates adjusted for age group, comorbidities, indigenous ethnicity and pregnancy; Chile estimates adjusted for age, month of symptom onset and pre-existing conditions; New Zealand estimates adjusted for age group; South Africa estimates adjusted for seasonality and age.

A(H3N2). Early estimates often approximate final estimates [12]. However, the utility of these estimates for the northern hemisphere may be limited because the 2019 southern hemisphere vaccine differed from the 2019/20 northern hemisphere formulation in three of four components, A(H1N1)pdm09, A(H3N2) and B/Victoria. Nevertheless, these estimates or earlier versions of them were included with other data reviewed at the WHO Consultation and Information Meeting on the Composition of Influenza Virus Vaccines for Use in the 2020 Southern Hemisphere Influenza Season during 23–26 September 2019 in Geneva and provided a general impression of the performance of the 2019 vaccine.

While heterogeneity in our VE estimates did not exceed an I^2 of 60%, with so few studies, the sensitivity of statistical tests to detect heterogeneity is probably limited. This is exemplified by the I^2 of 0% for influenza B estimates among adults despite differences in VE point estimates of 75 percentage points (Figure 2). Thus, low heterogeneity statistics do not alleviate concerns about how to interpret discrepant VE point estimates.

There are many potential sources for this heterogeneity that affect not only the VE estimates, but interpretation of weekly activity rates. First, with random sampling, we should not expect estimates to be the same [13]. Second, when samples are small they may be vulnerable to statistical biases, such as sparse data bias, and bias due to measurement errors may be more profound [14]. Third, there were many differences in study design (Table). Case ascertainment differed; for example, a SARI case definition was used in New Zealand and Chile, but not in Australian hospital surveillance. Exposure ascertainment also differed, with varying availability of registries to verify vaccination status and the use of different vaccines. In particular, the adjuvanted vaccines used among Australians ≥ 65 years of age might be expected to yield higher VE than standard vaccines [15]. Fourth, vaccine coverage varied (Table). Low vaccination coverage, as observed in South Africa, affects power and precision and can exacerbate the bias induced by measurement errors. Higher coverage, as seen in Chile and among elderly patients in New Zealand and Australia, may mean that many more people in the sample are repeat vaccinees. Repeat vaccination may negatively impact VE and could result in lower VE estimates in highly vaccinated populations [16]. Finally, although only limited virological data were available, we observed differences in circulating A(H3N2) virus clades and B lineages. This may impact both seasonality and VE, particularly as most A(H3N2) viruses sequenced appeared to be in different clades from the vaccine virus (3C.2a2). Notably, most A(H3N2) viruses were also in different genetic groups from the 2019/20 northern hemisphere vaccine (3C.3a).

In conclusion, we have attempted to briefly summarise and interpret the 2019 influenza season in four southern hemisphere countries and have presented early VE estimates. We observed substantial variation in available data on influenza seasonality and VE within the southern hemisphere in 2019, which is unsurprising given the many differences in surveillance among these countries. Caution should be applied when attempting to infer the impending northern hemisphere influenza season based on these observations.

Ethical statements
Australia: Data were collected, used and reported under the legislative authorisation of the Australian state and territory legislation, and thus did not require Human Research Ethics Committee approval.

Chile: The institutional review boards at the Pan American Health Organization and United States CDC reviewed the protocol and considered it a vaccination effectiveness evaluation (non-intervention study). Monitoring vaccine effectiveness in Chile is an objective of severe acute respiratory surveillance; thus, ethics committee approval was not needed for data collection and analysis. We did not collect personal identifiers.

New Zealand: Influenza surveillance in New Zealand is conducted in accordance with the Public Health Act and thus ethics committee approval was not needed for collection or use of these data.

South Africa: Influenza surveillance is conducted in accordance with the Public Health Act and thus ethics committee approval was not needed for collection or use of these data.

References

1. Paules CI, Sullivan SG, Subbarao K, Fauci AS. Chasing Seasonal Influenza - The Need for a Universal Influenza Vaccine. N Engl J Med. 2018;378(1):7-9. https://doi.org/10.1056/NEJMp1714916 PMID: 29185857
2. Sullivan SG, Chilver MB, Carville KS, Deng YM, Grant KA, Higgins G, et al. Low interim influenza vaccine effectiveness, Australia, 1 May to 24 September 2017. Euro Surveill. 2017;22(43). https://doi.org/10.2807/1560-7917.ES.2017.22.43.17-00707 PMID: 29090681
3. Cheng AC, Holmes M, Dwyer DE, Irving L, Korman T, Senenayake S, et al. Influenza epidemiology in patients admitted to sentinel Australian hospitals in 2016: the Influenza Complications Alert Network (FluCAN). Commun Dis Intell Q Rep. 2017;41(4):E337-47. PMID: 29864387
4. Sotomayor V, Fasce RA, Vergara N, De la Fuente F, Loayza S, Palekar R. Estimating the burden of influenza-associated hospitalizations and deaths in Chile during 2012-2014. Influenza Other Respir Viruses. 2018;12(1):138-45. https://doi.org/10.1111/irv.12502 PMID: 29446231
5. Bissielo A, Pierse N, Huang QS, Thompson MG, Kelly H, Mishin VP, et al. Effectiveness of seasonal influenza vaccine in preventing influenza primary care visits and hospitalisation in Auckland, New Zealand in 2015: interim estimates. Euro Surveill. 2016;21(1):30101. https://doi.org/10.2807/1560-7917.ES.2016.21.1.30101 PMID: 26767540
6. Tempia S, Walaza S, Moyes J, Cohen AL, McMorrow ML, Treurnicht FK, et al. Quantifying How Different Clinical Presentations, Levels of Severity, and Healthcare Attendance Shape the Burden of Influenza-associated Illness: A Modeling Study From South Africa. Clin Infect Dis. 2019;69(6):1036-48. https://doi.org/10.1093/cid/ciy1017 PMID: 30508065
7. Kyeyagalire R, Tempia S, Cohen AL, Smith AD, McAnerney JM, Dermaux-Msimang V, et al. Hospitalizations associated with influenza and respiratory syncytial virus among patients attending a network of private hospitals in South Africa, 2007-2012. BMC Infect Dis. 2014;14(1):694. https://doi.org/10.1186/s12879-014-0694-x PMID: 25510622
8. McAnerney JM, Walaza S, Tempia S, Blumberg L, Treurnicht FK, Madhi SA, et al. Estimating vaccine effectiveness in preventing laboratory-confirmed influenza in outpatient settings in South Africa, 2015. Influenza Other Respir Viruses. 2017;11(2):177-81. https://doi.org/10.1111/irv.12436 PMID: 27865064
9. Vega T, Lozano JE, Meerhoff T, Snacken R, Beauté J, Jorgensen P, et al. Influenza surveillance in Europe: comparing intensity levels calculated using the moving epidemic method. Influenza Other Respir Viruses. 2015;9(5):234-46. https://doi.org/10.1111/irv.12330 PMID: 26031655
10. Sullivan SG, Feng S, Cowling BJ. Potential of the test-negative design for measuring influenza vaccine effectiveness: a systematic review. Expert Rev Vaccines. 2014;13(12):1571-91. https://doi.org/10.1586/14760584.2014.966695 PMID: 25348015
11. Higgins JP, Thompson SG. Quantifying heterogeneity in a meta-analysis. Stat Med. 2002;21(11):1539-58. https://doi.org/10.1002/sim.1186 PMID: 12111919
12. Leung VK, Cowling BJ, Feng S, Sullivan SG. Concordance of interim and final estimates of influenza vaccine effectiveness: a systematic review. Euro Surveill. 2016;21(16):30202. https://doi.org/10.2807/1560-7917.ES.2016.21.16.30202 PMID: 27124573
13. Krzywinski M, Altman N. Points of significance: Importance of being uncertain. Nat Methods. 2013;10(9):809-10. https://doi.org/10.1038/nmeth.2613 PMID: 24143821
14. Greenland S. Small-sample bias and corrections for conditional maximum-likelihood odds-ratio estimators. Biostatistics. 2000;1(1):113-22. https://doi.org/10.1093/biostatistics/1.1.113 PMID: 12933529
15. Mannino S, Villa M, Apolone G, Weiss NS, Groth N, Aquino I, et al. Effectiveness of adjuvanted influenza vaccination in elderly subjects in northern Italy. Am J Epidemiol. 2012;176(6):527-33. https://doi.org/10.1093/aje/kws313 PMID: 22940713
16. Belongia EA, Skowronski DM, McLean HQ, Chambers C, Sundaram ME, De Serres G. Repeated annual influenza vaccination and vaccine effectiveness: review of evidence. Expert Rev Vaccines. 2017;16(7):723-26. https://doi.org/10.1080/14760584.2017.1334554 PMID: 28562111

License, supplementary material and copyright

Check for updates